You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨藥明巨諾-B(2126.HK)續升9%創2個月新高 4日累計漲幅近40%
格隆匯 12-24 11:04
格隆匯12月24日丨藥明巨諾-B(2126.HK)大幅拉昇漲近9%,4日連漲近40%。報15.56港元創2個月新高價,總市值64億港元。近日,廣東省藥品交易中心公示廣東省第三方藥品電子交易平台新獲批上市的新品種(第四批)及其擬掛網價格,上海藥明巨諾CAR-T產品瑞基奧侖賽注射液(商品名:倍諾達)位列其中,擬掛網價格為129萬。據悉,倍諾達已在國內獲批,用於治療經過二線或以上系統性治療後成人患者的復發或難治性大B細胞淋巴瘤患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account